PTIX
Protagenic Therapeutics, Inc.newCompany with tickers: PTIX, PTIXW
CIK
1022899
CUSIP
74365N301
Shares Outstanding
1,810,208
Website
https://protagenic.com
Investor Relations
https://protagenic.com/investor-relations
13F Activity (30d)
2 filings
1 filers
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | $0 | USD | 2025-12-31 | 10-Q | 2026-03-09 |
| Revenue (ASC 606) | — | ||||
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $925,103 | USD | 2025-12-31 | 10-Q | 2026-03-09 |
| Research & Development | $153,786 | USD | 2025-12-31 | 10-Q | 2026-03-09 |
| Operating Income | $-925,103 | USD | 2025-12-31 | 10-Q | 2026-03-09 |
| Net Income | $2,210,769 | USD | 2025-12-31 | 10-Q | 2026-03-09 |
| EPS (Basic) | $1.14 | USD/shares | 2025-12-31 | 10-Q | 2026-03-09 |
| EPS (Diluted) | $1.14 | USD/shares | 2025-12-31 | 10-Q | 2026-03-09 |